Zogenix seeks US FDA OK for single-entity hydrocodone in lucrative pain market
This article was originally published in Scrip
Executive Summary
Looking to take another bite out the $20 billion pain market pie and confident it is ready to again obtain the US FDA's OK, Zogenix submitted its new drug application (NDA) for its oral extended-release hydrocodone therapy Zohydro – seeking to gain the agency's blessing to market the experimental medicine in the US as a treatment for chronic pain.